In conclusion, this is the second study to show non-inferiority of anti-VEGF therapy to PRP and the first study to show superiority of an anti-VEGF agent to PRP in eyes with PDR. If society is willing to pay £1400 for an additional 1-point improvement in BCVA, then aflibercept has a 56.60% probability of being cost-effective at the list price of £816. The trial outcomes are further augmented by the higher satisfaction scores of patients treated with aflibercept than with PRP. However, this is a 52-week study while PDR is a lifelong condition and so longer-term studies are required to evaluate long-term patient compliance and the disease-modifying effect of anti-VEGF agents in PDR. Therefore, the clinical effectiveness and cost-effectiveness of the different anti-VEGF agents in PDR have to be evaluated in Phase III clinical trials for global adoption of anti-VEGF as a treatment adoption for PDR.
Intravitreal aflibercept compared with panretinal photocoagulation for proliferative diabetic retinopathy: the CLARITY non-inferiority RCT · Conclusion
Conclusion
Attribution. Sobha Sivaprasad; Philip Hykin; A Toby Prevost; Joana Vasconcelos; Amy Riddell; Jayashree Ramu et al. (2018). Intravitreal aflibercept compared with panretinal photocoagulation for proliferative diabetic retinopathy: the CLARITY non-inferiority RCT. NIHR Journals Library. Copyright © Queen’s Printer and Controller of HMSO 2018. This work was produced by Sivaprasad et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK. Licensed under CC BY 4.0. NCBI Bookshelf NBK531673. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.